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Abstract Cystatin C with the 11 N-terminal amino acids
truncated shows a much lower affinity for cysteine proteinases
than the intact inhibitor. Such truncation of cystatin C is
recorded after action of glycyl endopeptidase and cathepsin L.
Incubation of cystatin C with papain, cathepsin B or cathepsin H
led to no changes in the cystatin C molecule. Isoelectric focusing
of the cathepsin L and cystatin C mixture showed the formation
of two new bands. One of them appeared whether E-64 or PMSF
was added or not, evidently representing a cystatin C/cathepsin L
complex. The other band is the truncated cystatin C molecule. N-
terminal sequencing after separation by HPLC showed that
cystatin C is cleaved by cathepsin L at the Gly11-Gly12 bond.
The action of cathepsin L on cystatin C may be explained by the
cleavage of the scissile bond in an inappropriate complex.
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1. Introduction
Human cystatin C is the most studied extracellular low
molecular weight inhibitor of cysteine proteinases. It consists
of 120 amino acid residues with two disul¢de bridges and
belongs to family 2 of the cystatin superfamily [1^4]. It is
widespread in human tissues, and is found mainly in secre-
tions and extracellular £uids such as cerebrospinal £uid, semi-
nal plasma, milk, synovial £uid, urine, saliva and blood plas-
ma [5,6]. It is thought that cystatin C is the physiologically
most important inhibitor, regulating activities of endogenous
cysteine proteinases such as cathepsins B, H, L and S in the
extracellular environment. On the basis of the crystal struc-
tures of chicken cystatin and the ste¢n B/papain complex, it
has been shown that three contiguous regions on the folded
human cystatin C polypeptide chain are involved in the inter-
action with the proteinase active site cleft [7,8]. Two evolutio-
narily conserved hairpin loop segments correspond to the
Gln55-Ile-Val-Ala-Gly59 and Pro105-Trp106 regions in the
C-terminal part of the molecule. The third enzyme binding
region of human cystatin C is the N-terminal part with the
conserved Gly11 residue. Truncation of the inhibitor by 10 or
11 N-terminal residues results in major loss of a⁄nity for the
target enzyme [9^12]. These ¢ndings indicate that the main
signi¢cance of the conserved Gly11 residue of cystatin C is
to allow adaptation of the N-terminal segment in a conforma-
tion optimal for interaction with the active site region of cys-
teine proteinase [9,13]. The ¢rst 10 amino acid residues are
missing in the cystatin C variant isolated from amyloid depos-
its of patients with hereditary cystatin C amyloid angiopathy
[15,16]. Di¡erently truncated forms of cystatin C, together
with the full-length form, were found in urine of patients
with nephrological disorders [14]. Leukocyte elastase was
shown to cleave a single bond between Val10 and Gly11 at
the N-terminal end of cystatin C in vitro [9]. Since both pro-
teins are extracellular it was suggested that such a cleavage
could be of physiological importance by controlling the extent
of inhibition of cysteine proteinases, especially cathepsin B, at
the site of in£ammation [9]. It is believed that these trunca-
tions are the result of proteolytic cleavage of full-length cys-
tatin C, since the N-terminal part of the inhibitor molecule is
exposed and has no ordered structure in solution [17].
In the present work we have investigated whether cysteine
proteinases are involved in the formation of N-terminally
truncated cystatin C variants detected by isoelectric focusing
(IEF) in samples of normal and ‘pathological’ urine [14], in
particular those truncated by 10 or 11 residues with signi¢-
cantly lower inhibitory activity.
2. Materials and methods
2.1. Materials
Bz-DL-Arg-NA, Arg-NA, E-64, PMSF and 2 times crystallized pa-
pain (EC 3.4.22.2) were obtained from Sigma Chemical Co. (St.
Louis, MO, USA). Z-Phe-Arg-MCA and Arg-MCA were from Bach-
em (Bubendorf, Switzerland). Coomassie brilliant blue G-250 was
from Bio-Rad (USA). E-64 was from Peptide Research Foundation
(Osaka, Japan). Superdex 75 HR10/30, 8^25% polyacrylamide gra-
dient gels, low molecular weight calibration kit, polyacrylamide gels
with Pharmalyte pH 3^9 and broad pI kit were supplied by Amer-
sham Pharmacia Biotech (Uppsala, Sweden). The Chromspher C8
column was from Chrompack (Frankfurt, Germany). Glycyl endopep-
tidase (EC 3.4.22.25) was a generous gift from Dr. Alan J. Barrett,
Strangeways Research Laboratory, Cambridge, UK.
2.2. Puri¢cation of cysteine proteinases
Human cathepsin B (EC 3.4.22.1), cathepsin H (EC 3.4.22.16) and
cathepsin L (EC 3.4.22.15) were puri¢ed from human kidney by the
method involving gel ¢ltration, covalent chromatography on thiol-
Sepharose and cation exchange chromatography [18]. Papain from
Sigma was additionally puri¢ed by FPLC on a Mono S column using
0.02 M sodium acetate bu¡er, pH 5.0, containing 1 mM EDTA.
Papain was eluted with a linear gradient of NaCl (0^0.5 M). Concen-
trations of cathepsins and papain were determined taking A280 (1%)
for cathepsin B to be 18, for cathepsins H and L 14 [19] and for
papain 25 [20]. Active concentrations of cathepsins B, L and papain
were determined by titration with E-64 [21], while the active concen-
tration of cathepsin H was obtained by titration with ste¢n A [22].
2.3. Puri¢cation of cysteine proteinase inhibitors
The full-length form of human cystatin C was isolated from urine
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of patients with various nephrological disorders by the modi¢ed meth-
od of Brzin et al. [2,14] using gel ¢ltration, a⁄nity chromatography
on carboxymethylated papain-Sepharose and ion exchange chroma-
tography. Recombinant human cystatin C, which di¡ered from the
wild-type protein by three additional amino acid residues (Gly-Ser-
Met) at the N-terminal end, was prepared as described previously [23].
In most experiments human recombinant cystatin C was used, since it
was available in su⁄cient amounts and exhibited essentially identical
physicochemical properties to the native protein, including Ki values
for tested cysteine proteinases [23,24].
Ste¢n A was puri¢ed from human leukocytes [25]. Concentrations
of inhibitors were determined spectrophotometrically, taking A280
(1%) for cystatin C and ste¢n A to be 8.5 and 7.4, respectively, as
calculated from the amino acid composition. The percent of fully
active cystatin C was obtained by titration with titrated papain [23].
All concentration stated below refer to the active forms of enzymes
or inhibitors.
2.4. Treatment of cystatin C and ste¢n A with proteinases
Recombinant cystatin C and ste¢n A were incubated separately at a
¢nal concentration of 0.5 mg/ml with glycyl endopeptidase, papain,
cathepsin B, cathepsin H and cathepsin L at di¡erent molar ratios at
37‡C. Bu¡ers used were the same as for enzyme assays [23,26]. After
di¡erent times samples were taken and the reaction stopped by adding
5 mM E-64. The e¡ect of enzyme action was monitored by PAGE in
the presence of SDS and by IEF. SDS-PAGE was carried out in an 8^
25% polyacrylamide gradient gel on the PhastSystem apparatus as
recommended by the manufacturer. Gels were stained with 0.2% Coo-
massie brilliant blue G-250. A low molecular weight calibration kit
was used. IEF was carried out on polyacrylamide gels with Pharma-
lyte carrier ampholines in the pH range of 3^9, using the PhastSystem
apparatus, as recommended by the manufacturer. A mixture of stand-
ard proteins was run parallel to the samples. Gels were stained with
Coomassie brilliant blue G-250.
2.5. Preparation and puri¢cation of N-terminally truncated cystatin C
Recombinant cystatin C was incubated with glycyl endopeptidase in
0.1 M phosphate bu¡er, pH 6.5, containing 2 mM dithiothreitol and
1.5 mM EDTA, for 4 h at 37‡C in a molar ratio of enzyme to
inhibitor of 1:100. The truncated cystatin C was then puri¢ed by
gel chromatography on a Superdex 75 column on FPLC system, using
0.1 M ammonium bicarbonate bu¡er, pH 8.0.
Cystatin C truncated by cathepsin L was made by incubating re-
combinant cystatin C at a ¢nal concentration of 0.5 mg/ml with ca-
thepsin L in an enzyme/inhibitor ratio of 1:8, in 0.34 M sodium
acetate bu¡er, pH 5.5, containing 2 mM dithiothreitol and 1.5 mM
EDTA for 4 h at 37‡C. The cleavage products were puri¢ed by HPLC
on a C8 Chromspher column, using an acetonitrile gradient (0^80%)
in 0.1% tri£uoroacetic acid. Eluted proteins were N-terminally se-
quenced using an Applied Biosystems 475 liquid sequencer connected
on-line to a 120 A phenylthiohydantoin amino acid analyzer from the
same manufacturer.
2.6. Determination of inhibition constants
Inhibition kinetics of cathepsins B, H and L were studied under
pseudo-¢rst-order conditions [27] in continuous kinetic assays, and
followed using a Perkin Elmer LS-3 spectro£uorimeter, connected to
an IBM personal computer, running Flusys software [28]. Truncated
cystatin C in various concentrations was mixed with substrate solu-
tion in the £uorimetric cuvette. The reaction was initiated by the
addition of the enzyme in a negligible volume. Cathepsin B was as-
sayed in 0.1 M sodium phosphate bu¡er, pH 6.0, cathepsin H in 0.1
M sodium phosphate bu¡er, pH 7.0, and cathepsin L in 0.34 M
sodium acetate bu¡er, pH 5.5. All bu¡ers contained 1.5 mM EDTA
and 2 mM dithiothreitol. The substrates used were Z-Phe-Arg-MCA
for cathepsins B and L and Arg-MCA for cathepsin H, all at 5 WM
¢nal concentration. Apparent Ki values were calculated by linear re-
gression analysis of the initial and steady-state rates of substrate hy-
drolysis obtained at di¡erent inhibitor concentrations according to
Morrison [29]. The Ki values were corrected for substrate competition
with the use of Km values for these enzymes [23].
3. Results
The purity of cathepsin L used in these experiments was
checked by SDS-PAGE, IEF and N-terminal analysis. The
preparation of the enzyme contained about 50% of active
enzyme. The proportions of inhibitory active recombinant
and native cystatin C used in these experiments were about
71% and 55%, respectively, as determined by titration with
papain.
Incubation of recombinant human cystatin C with cathep-
sin L in an enzyme/inhibitor molar ratio of 1:8 at 37‡C re-
sulted in gradual conversion of full-length cystatin C into the
truncated form, as revealed by SDS-PAGE (Fig. 1). Overnight
incubation of recombinant cystatin C with cathepsin L even-
tually resulted in complete disappearance of the cystatin C
band (not shown). A control experiment with cystatin C alone
in the same bu¡er at 37‡C revealed no breakdown of the
inhibitor, even after 24 h incubation. The ability of cathepsin
L to cleave the native full-length human cystatin C with pI 9.2
isolated from urine was also tested on SDS-PAGE. The result
was similar to that with recombinant inhibitor (not shown).
Incubating recombinant cystatin C with glycyl endopeptidase
in an enzyme/inhibitor molar ratio of 1:100 for 30 min re-
sulted in similar truncation of cystatin C (Fig. 1).
Isoelectric focusing of the mixture of recombinant human
cystatin C and cathepsin L in molar ratio 8:1 assayed after 3 h
of incubation showed a band with pI 9.2 and formation of a
new major band with pI 8.1 and a weak band with pI 8.25
(Fig. 2). Formation of these two bands was not prevented by
addition of PMSF to the incubation mixture at a ¢nal con-
centration of 50 mM. On the other hand, addition of E-64 to
the enzyme at a ¢nal concentration of 1 mM completely abol-
ished the appearance of these new bands. In addition, a band
with pI 5.9 appeared in all incubation mixtures, including
those containing PMSF and E-64, probably due to the for-
mation of cystatin C/cathepsin L complex since the isoelectric
point of cathepsin L is 5.4. When cystatin C was incubated
Fig. 1. Cleavage of recombinant human cystatin C by cathepsin L
and glycyl endopeptidase detected by SDS-PAGE. Lanes 1^3 indi-
cate cystatin C after incubation with cathepsin L at a molar ratio
of 8:1 for 2, 4 and 6 h, respectively, at 37‡C. Lane 4: cystatin C
after incubation with glycyl endopeptidase in molar ratio 100:1 for
30 min at 37‡C. Incubation bu¡ers were as indicated in Section 2.
Standard proteins are indicated with ST and cystatin C with cC.
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with glycyl endopeptidase in an enzyme/inhibitor molar ratio
of 1:100 for a short period (about 10 min) the bands with pI
8.1 and 8.25 appeared. Prolonged incubation resulted in for-
mation of a single band with pI 8.1. No band presumably
corresponding to cystatin C and glycyl endopeptidase complex
could be detected in isoelectric focusing gel.
SDS-PAGE of incubation mixtures of cystatin C with pa-
pain in molar ratio 5:1, with cathepsin B in molar ratio 4:1 or
cathepsin H in molar ratio 4:1, all in appropriate incubation
bu¡ers for 5 h at 37‡C, revealed only intact cystatin C, with
no truncation being observed (Fig. 3).
Experiments to examine the e¡ect of di¡erent enzymes on
ste¢n A were performed by mixing ste¢n A with cathepsin B,
cathepsin L or papain, all in a molar ratios 4:1, and with
glycyl endopeptidase in molar ratio 50:1, in appropriate in-
cubation bu¡ers for 5 h at 37‡C. In all cases SDS-PAGE of
the incubation mixtures revealed no change in ste¢n A poly-
peptide chain (not shown).
To elucidate the nature of the cleavage of cystatin C with
cathepsin L, 0.5 mg of recombinant cystatin C was mixed with
cathepsin L in a ratio of 8:1 for 4 h at 37‡C. The reaction was
terminated by addition of E-64 to 1 mM ¢nal concentration.
The incubation mixture was resolved into two peaks on C8
Chrompack column on the HPLC system under acetonitrile
gradient (Fig. 4). Both peaks were N-terminally sequenced.
The ¢rst peak contained the N-terminally truncated cystatin
C with sequence starting with Gly12 (Gly-Pro-Met-Asp-Ala-),
according to human cystatin C numbering, and a minor con-
tamination with cathepsin L. The second peak corresponded
to the intact recombinant human cystatin C with N-terminal
sequence starting with Gly(-3) (Gly-Ser-Met-Ser-Ser-Pro-).
Larger amounts of truncated human cystatin C, lacking the
¢rst 11 N-terminal amino acids, were obtained by incubating
2.5 mg of recombinant human cystatin C with glycyl endo-
peptidase in a ratio of 1:100 for 4 h. SDS-PAGE of the in-
cubation mixture revealed total conversion of the recombinant
cystatin C into the truncated form. After puri¢cation on
Superdex 75 the truncated inhibitor was used for inhibition
studies. By continuous rate assays equilibrium dissociation
constants (Ki) for complexes of the truncated inhibitor with
cathepsins H and L were determined, while the value for
cathepsin B was estimated to be more than 500 nM. The
results agree well with the determinations of Hall et al. [10].
The N-terminal truncation of human cystatin C thus strongly
a¡ected the a⁄nity of the inhibitor for all the enzymes tested.
Ki values for cathepsin B and cathepsin L increased by at least
three orders of magnitude and for cathepsin H by about two
orders of magnitude.
Fig. 2. Cleavage of recombinant human cystatin C by cathepsin L
detected by isoelectric focusing. Cystatin C was incubated for 2 h at
37‡C with cathepsin L at a ratio of 8:1 in the incubation bu¡er as
indicated in Section 2 (lane 3). Lanes 4 and 5: PMSF (10 mM) and
E-64 (1 mM), respectively, were added to the enzyme before the in-
cubation with the inhibitor. Lanes 1 and 2: cystatin C and ca-
thepsin L were applied separately at the same concentrations and
after incubation as above.
Fig. 3. SDS-PAGE of the incubation mixtures of recombinant hu-
man cystatin C with papain, cathepsin B and cathepsin H. Cystatin
C was incubated for 5 h with papain (lane 2), cathepsin B (lane 3),
or cathepsin H (lane 4), all in ratios 4:1 in incubation bu¡ers as de-
scribed in Section 2. In lane 1 cystatin C was applied. Standard pro-
teins are indicated with ST.
Fig. 4. Separation of the incubation mixture of the recombinant hu-
man cystatin C with cathepsin L on C8 Chromspher column of the
HPLC system. A 0^60% gradient of acetonitrile was applied. As de-
termined by N-terminal sequencing, peak (a) corresponds to trun-
cated cystatin C, starting with Gly12, and peak (b) intact recombi-
nant human cystatin C.
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4. Discussion
The majority of our experiments were performed using a
recombinant cystatin C extended by three amino acids at its
N-terminus, which was comparable to the wild-type cystatin C
with respect to all the physicochemical properties tested. The
expression product showed a molar inhibitory activity of 71%.
The additional three amino acid residues are not expected to
in£uence the binding of the inhibitor to the proteinase, as the
¢rst 10 amino acid residues in cystatins have been shown to be
unstructured and highly mobile [17], and pointing away from
the proteinase surface [7]. Control experiments with full-
length cystatin C of human origin were also performed. Its
homogeneity was checked by the usual electrophoretic meth-
ods and by N-terminal analysis. It displayed a molar inhib-
itory activity of 55%, a value commonly observed for prepa-
rations of this inhibitor from human sources [30]. Our data,
which document initial complex formation, followed by trun-
cation of cystatin C by cathepsin L, with which it is mixed in
excess, cannot be adequately explained by the assumption of a
common mode of interaction with target proteinases for all
cystatins [7]. This presumes that, in contrast to standard sub-
strates, the inhibitor’s N-terminal trunk will be su⁄ciently
removed from the proteinase catalytic residues in the complex
and thus not be cleaved.
Four possible causes for the Gly11-Gly12 bond to become
substrate-like for proteolytic cleavage with cathepsin L can be
envisaged: (a) a minute amount of glycyl endopeptidase, orig-
inating as contamination of the papain bonded to Sepharose
used for the isolation of cystatin C, (b) the presence of an
atypical cysteine proteinase in the puri¢ed cathepsin L prep-
aration, (c) conformational change in cystatin C that renders
the Gly11-Gly12 bond susceptible to hydrolysis, and (d) hy-
drolysis of the sensitive bond of cystatin C in complex with
cathepsin L by a free cathepsin L molecule.
Cleavage of the bond by contaminating glycyl endopepti-
dase in the cystatin C preparation was ruled out by control
experiments with cystatin C alone, which revealed no break-
down of the inhibitor.
Although cathepsin L was shown to be homogeneous by N-
terminal analysis, SDS-PAGE and IEF, its activity was about
50%, which may re£ect the presence of atypical, partly inacti-
vated (abnormal/denatured) molecules, possibly partly de-
graded by autolysis or by reduction of disul¢de bonds. One
could envisage a di¡erent mode of interaction of the N-termi-
nus of cystatin C with atypical cathepsin L, as a result of
di¡erences in the active site region of the latter. On the other
hand, the presence of a minute quantity of a cysteine protein-
ase with glycyl endopeptidase speci¢city co-puri¢ed with ca-
thepsin L cannot be completely ruled out, although no pro-
tease with similar properties has been reported from human
origin. Reactive glycyl bonds in free cystatin C molecules
could be cleaved, while those engaged in complex with cathep-
sin L would be protected within the complex. Our observa-
tion that all cystatin C is entirely degraded therefore does not
support the above possibility. It should be added that a prep-
aration of bovine cathepsin L behaved identically to human
enzyme (our observation) and that human cathepsins B and H
and papain showed no cleavage.
Given the evidence presented here the most probable cause
for the Gly11-Gly12 hydrolysis could be conformational dis-
tortion in the cystatin C molecule within the cystatin C/ca-
thepsin L complex, which brings the Gly11-Gly12 bond into a
substrate-like position. A similar phenomenon was observed
in complexes of papain and cathepsin L with mutants of
chicken cystatin characterized by distorted contacts of one
of the hairpin loops [31]. The Gly9-Ala10 bond in chicken
cystatin, analogous to the Gly11-Gly12 bond in cystatin C,
was cleaved in a substrate-like manner, resulting in a trun-
cated inhibitor of much lower activity and dissociation of the
complex.
The calculated value of 71% for molar inhibitor concentra-
tion may represent two populations of cystatin C molecules,
those that are fully active, and those that carry small local
conformational changes and have a lower binding a⁄nity for
cathepsin L, and with the Gly11-Gly12 bond suitably located
to be cleaved within the complex. As papain, cathepsin B and
cathepsin H are inactive under the same conditions, it can be
concluded that the mode of interaction of the N-terminal
region with target proteinases depends also on the enzyme
and re£ects structural particularities in the active site region
of the latter.
On the other hand, the truncation of cystatin C could be
explained as the attack of the second cathepsin L molecule on
the cathepsin L/cystatin C complex. The phenomenon of the
action of a second enzyme molecule on an enzyme/inhibitor
complex has been observed by Berti and Storer [32] studying
proteolytic susceptibility of cystatin C depending on acidic
pH-dependent local conformational changes, where the sec-
ond papain molecule acts on a papain/inhibitor complex by
cleavage of the exposed regions in the inhibitor molecule. In
our case N-terminal cleavage of cystatin C by free cathepsin L
in solution is not likely for several reasons. The amount of
free cathepsin L in solution would be negligible, judging from
the very low inhibition constant of 10312 M, and it would be
further reduced by the initial excess of cystatin C. The Gly11-
Gly12 bond under the experimental conditions would be
buried in the complex, therefore shielded from cleavage by
the free enzyme if present. However, the stability of the native
inhibitor towards unfolding would be reduced in the lysoso-
mal pH range of 4.5^5.0, therefore, according to this mecha-
nism, enabling rapid degradation of cystatin C after it had
been sequestered free or complexed into the lysosome, in or-
der to prevent intra-lysosomal accumulation of non-degrad-
able proteins.
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